Mara Goldstein
Stock Analyst at Mizuho
(2.62)
# 1,052
Out of 5,072 analysts
69
Total ratings
48.08%
Success rate
16.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $12.14 | +147.12% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.47 | +304.86% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $10.64 | -24.81% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $26.10 | +60.92% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $17.32 | +188.68% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $19.82 | +127.04% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $104.46 | -26.29% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $3.17 | +120.82% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.14 | +601.75% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $65.21 | +38.02% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $9.15 | -61.75% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.98 | +18,081.82% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $7.66 | +161.10% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $104.83 | +24.01% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.28 | -53.22% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.41 | +751.06% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $68.13 | -70.64% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $7.51 | +539.15% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.96 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.82 | +140.76% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $12.14
Upside: +147.12%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.47
Upside: +304.86%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $10.64
Upside: -24.81%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $26.10
Upside: +60.92%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $17.32
Upside: +188.68%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $19.82
Upside: +127.04%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $104.46
Upside: -26.29%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $3.17
Upside: +120.82%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.14
Upside: +601.75%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $65.21
Upside: +38.02%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $9.15
Upside: -61.75%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.98
Upside: +18,081.82%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $7.66
Upside: +161.10%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $104.83
Upside: +24.01%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.28
Upside: -53.22%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.41
Upside: +751.06%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $68.13
Upside: -70.64%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $7.51
Upside: +539.15%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $26.96
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.82
Upside: +140.76%